Immunotherapy

Submit request or call to make an appointment.

Immunotherapy is a new approach to cancer treatment and a specialty of physicians at Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine.

Board-certified and fellowship-trained geneticists, pediatric oncologists and other specialists work together to tailor immunotherapy treatments that can provide new and effective options.

Changes to our genes — especially those that control how cells grow and divide — cause cancer. Some of these genetic changes are inherited and some aren’t. Our genetic oncologists and hematologists are at the leading edge of identifying diagnostic methods and treatments based on genetics.

Cancer-causing genetic changes often lead to the appearance of novel proteins that are recognized by our immune cells as foreign. In cancer immunotherapy, the goal is to harness the ability of our immune cells to recognize these cancer-associated proteins and stimulate the immune system to reject or destroy tumors. Immunotherapies can either boost the immune system or train the immune system to attack cancer cells.

The Norton Children’s immunotherapy program focuses on combining immunotherapy with conventional cancer treatments. Chemotherapy is used to remove the bulk of the malignant disease, and immunotherapy is added to eliminate any residual cancer cells, which could come back and cause disease relapse if they are left untreated.

William T. Tse, M.D., Ph.D., joined the Norton Children’s Cancer Institute team from the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In addition to his groundbreaking research, Dr. Tse brings a clinical focus on using less toxic methods of stem cell transplants. He’s found success with reduced-intensity conditioning transplant for children with severe immune deficiency. Patients tend to tolerate the new approach better, effectively rebuilding their immune system and correcting underlying defects.

Dr. Tse currently is working with a team of clinicians and scientists from University of Louisville and Norton Cancer Institute to establish the laboratory capacity to produce clinical-grade immune cells derived from patients and engineered to recognize high-risk leukemia, neuroblastoma and brain tumor cells. Once these immune cells are infused back into the patient, they will find their targets and actively eliminate any residual leukemia and cancer cells. Patients tend to tolerate the new approach better, effectively rebuilding their immune system and correcting underlying defects.

This exciting immunotherapy approach represents a new frontier in the fight against childhood cancer and leukemia.

Available Immunotherapy Treatments

  • Monoclonal antibodies
  • Cellular therapies
  • Interleukins
  • Interferons
  • Granulocyte-macrophage colony-stimulating factor

Related Stories

10 facts about childhood cancer
Treatment options for recurrent low-grade glioma
Early symptoms of neuroblastoma can mimic other common childhood illnesses
Children with cyclic neutropenia are at higher risk of developing severe bacterial infections